Referências
Principais artigos
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
National Institute on Drug Abuse. Methamphetamine research report: what is methamphetamine? Oct 2019 [internet publication].Texto completo
Paulus MP, Stewart JL. Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiatry. 2020 Sep 1;77(9):959-66.Texto completo Resumo
Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment for stimulant use disorders: updated 2021. Treatment Improvement Protocol (TIP) series, no. 33. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1999 (updated 2021).Texto completo Resumo
World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Nov 2014 [internet publication].Texto completo
Siefried KJ, Acheson LS, Lintzeris N, et al. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. 2020 Apr;34(4):337-65.Texto completo Resumo
Soares E, Pereira FC. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups. Expert Opin Pharmacother. 2019 Dec;20(18):2273-93. Resumo
Artigos de referência
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
2. Kish SJ. Pharmacologic mechanisms of crystal meth. CMAJ. 2008 Jun 17;178(13):1679-82.Texto completo Resumo
3. Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013 May 1;129(3):167-79. Resumo
4. Moszczynska A. Neurobiology and clinical manifestations of methamphetamine neurotoxicity. Psychiatr Times. 2016 Sep;33(9):16-8.Texto completo Resumo
5. National Institute on Drug Abuse. Methamphetamine research report: what is methamphetamine? Oct 2019 [internet publication].Texto completo
6. Paulus MP, Stewart JL. Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiatry. 2020 Sep 1;77(9):959-66.Texto completo Resumo
7. United Nations Office on Drugs and Crime. World drug report 2022. Jun 2022 [internet publication].Texto completo
8. Stoneberg DM, Shukla RK, Magness MB. Global methamphetamine trends: an evolving problem. Int Crim Just Rev. 2017;28(2):136-61.Texto completo
9. European Monitoring Centre for Drugs and Drug Addiction. EU drug market: methamphetamine. 2022 [internet publication].Texto completo
10. European Monitoring Centre for Drugs and Drug Addiction. European drug report: trends and developments. 2022 [internet publication].Texto completo
11. Substance Abuse and Mental Health Services Administration (SAMHSA). 2021 National Survey of Drug Use and Health (NSDUH) releases. 2021 [internet publication].Texto completo
12. Chen T, Spiller HA, Badeti J, et al. Methamphetamine exposures reported to United States poison control centers, 2000-2019. Clin Toxicol (Phila). 2021 Aug;59(8):705-14. Resumo
13. Monitoring the Future. Methamphetamine: trends in last 12 months prevalence of use in 8th, 10th, and 12th grade. 2023 [internet publication].Texto completo
14. American Society of Addiction Medicine/American Academy of Addiction Psychiatry. The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024 May-Jun;18(1S):1-56.Texto completo
15. Centers for Disease Control and Prevention. CDC WONDERSearch: about underlying cause of death, 1999-2020. 2023 [internet publication].Texto completo
16. Hedegaard H, Bastian BA, Trinidad JP, et al. Drugs most frequently involved in drug overdose deaths: United States, 2011-2016. Natl Vital Stat Rep. 2018 Dec;67(9):1-14.Texto completo Resumo
17. Winkelman TNA, Admon LK, Jennings L, et al. Evaluation of amphetamine-related hospitalizations and associated clinical outcomes and costs in the United States. JAMA Netw Open. 2018 Oct 5;1(6):e183758.Texto completo Resumo
18. Hedegaard H, Bastian BA, Trinidad JP, et al. Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017. Natl Vital Stat Rep. 2019 Oct;68(12):1-16.Texto completo Resumo
19. Kariisa M, Scholl L, Wilson N, et al. Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017. MMWR Morb Mortal Wkly Rep. 2019 May 3;68(17):388-95.Texto completo Resumo
20. Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 2020 Apr;94(4):1085-133.Texto completo Resumo
21. Daniulaityte R, Silverstein SM, Crawford TN, et al. Methamphetamine use and its correlates among individuals with opioid use disorder in a Midwestern U.S. city. Subst Use Misuse. 2020;55(11):1781-9.Texto completo Resumo
22. Glick SN, Klein KS, Tinsley J, et al. Increasing heroin-methamphetamine (goofball) use and related morbidity among Seattle area people who inject drugs. Am J Addict. 2021 Mar;30(2):183-91.Texto completo Resumo
23. Glick SN, Burt R, Kummer K, et al. Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. Drug Alcohol Depend. 2018 Jan 1;182:86-92.Texto completo Resumo
24. Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment for stimulant use disorders: updated 2021. Treatment Improvement Protocol (TIP) series, no. 33. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1999 (updated 2021).Texto completo Resumo
25. Centers for Disease Control and Prevention. Annual surveillance report of drug-related risks and outcomes: United States, 2019. Nov 2019 [internet publication].Texto completo
26. Pro G, Hayes C, Montgomery BEE, et al. Demographic and geographic shifts in the preferred route of methamphetamine administration among treatment cases in the US, 2010-2019. Drug Alcohol Depend. 2022 Aug 1;237:109535. Resumo
27. Salo R, Flower K, Kielstein A, et al. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011 Apr 30;186(2-3):356-61.Texto completo Resumo
28. Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metab Brain Dis. 2014 Jun;29(2):351-7. Resumo
29. Zhou Y, Hu Y, Wang Q, et al. Association between white matter microstructure and cognitive function in patients with methamphetamine use disorder. Hum Brain Mapp. 2023 Feb 1;44(2):304-14.Texto completo Resumo
30. Hart CL, Marvin CB, Silver R, et al. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology. 2012 Feb;37(3):586-608.Texto completo Resumo
31. Basterfield C, Hester R, Bowden SC. A meta-analysis of the relationship between abstinence and neuropsychological functioning in methamphetamine use disorder. Neuropsychology. 2019 Jul;33(5):739-53. Resumo
32. Sung YH, Cho SC, Hwang J, et al. Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend. 2007 Apr 17;88(1):28-35. Resumo
33. Hall MG, Alhassoon OM, Stern MJ, et al. Gray matter abnormalities in cocaine versus methamphetamine-dependent patients: a neuroimaging meta-analysis. Am J Drug Alcohol Abuse. 2015;41(4):290-9. Resumo
34. Lyoo IK, Yoon S, Kim TS, et al. Predisposition to and effects of methamphetamine use on the adolescent brain. Mol Psychiatry. 2015 Dec;20(12):1516-24.Texto completo Resumo
35. Davidson C, Gow AJ, Lee TH, et al. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001 Aug;36(1):1-22. Resumo
36. Whitesell M, Bachand A, Peel J, et al. Familial, social, and individual factors contributing to risk for adolescent substance use. J Addict. 2013 Mar 20;2013:579310.Texto completo Resumo
37. Kilpatrick DG, Acierno R, Saunders B, et al. Risk factors for adolescent substance abuse and dependence: data from a national sample. J Consult Clin Psychol. 2000 Feb;68(1):19-30. Resumo
38. Hawkins JD, Catalano RF, Miller JY. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychol Bull. 1992 Jul;112(1):64-105. Resumo
39. Chen Y, Zhang J, Sun Y. The relationship between childhood abuse and depression in a sample of Chinese people who use methamphetamine. Int J Clin Health Psychol. 2019 Sep;19(3):181-8.Texto completo Resumo
40. Simpson JL, Grant KM, Daly PM, et al. Psychological burden and gender differences in methamphetamine-dependent individuals in treatment. J Psychoactive Drugs. 2016 Sep-Oct;48(4):261-9. Resumo
41. Svingen L, Dykstra RE, Simpson JL, et al. Associations between family history of substance use, childhood trauma, and age of first drug use in persons with methamphetamine dependence. J Addict Med. 2016 Jul-Aug;10(4):269-73. Resumo
42. Hendrickson RG, Horowitz BZ, Norton RL. "Parachuting" meth: a novel delivery method for methamphetamine and delayed-onset toxicity from "body stuffing". Clin Toxicol (Phila). 2006;44(4):379-82. Resumo
43. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990 Nov 21;264(19):2511-8. Resumo
44. O'Neil KA, Conner BT, Kendall PC. Internalizing disorders and substance use disorders in youth: comorbidity, risk, temporal order, and implications for intervention. Clin Psychol Rev. 2011 Feb;31(1):104-12. Resumo
45. Shadur JM, Lejuez CW. Adolescent substance use and comorbid psychopathology: emotion regulation deficits as a transdiagnostic risk factor. Curr Addict Rep. 2015 Dec 1;2(4):354-63.Texto completo Resumo
46. McKetin R, Kothe A, Baker AL, et al. Predicting abstinence from methamphetamine use after residential rehabilitation: findings from the Methamphetamine Treatment Evaluation Study. Drug Alcohol Rev. 2018 Jan;37(1):70-8. Resumo
47. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, et al; Methamphetamine Treatment Project Corporate Authors. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009 Apr;197(4):225-31.Texto completo Resumo
48. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Primary care-based interventions to prevent illicit drug use in children, adolescents, and young adults: US Preventive Services Task Force recommendation statement. JAMA. 2020 May 26;323(20):2060-6.Texto completo Resumo
49. Mullen JM, Richards JR, Crawford AT. Amphetamine related psychiatric disorders. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.Texto completo Resumo
50. Brecht ML, Herbeck D. Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug Alcohol Depend. 2014 Jun 1;139:18-25.Texto completo Resumo
51. Yimsaard P, Maes MM, Verachai V, et al. Pattern of methamphetamine use and the time lag to methamphetamine dependence. J Addict Med. 2018 Mar/Apr;12(2):92-8.Texto completo Resumo
52. Chen LY, Strain EC, Alexandre PK, et al. Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. Addict Behav. 2014 May;39(5):829-36.Texto completo Resumo
53. Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018 Dec 1;193:14-20. Resumo
54. Lineberry TW, Bostwick JM. Methamphetamine abuse: a perfect storm of complications. Mayo Clin Proc. 2006 Jan;81(1):77-84. Resumo
55. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006 Aug;26(8):1148-56. Resumo
56. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol (Phila). 2010 Aug;48(7):675-94. Resumo
57. Department of Health and Social Care. Drug misuse and dependence: UK guidelines on clinical management. Dec 2017 [internet publication].Texto completo
58. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014 Dec;28(12):1115-26.Texto completo Resumo
59. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007 Feb;120(2):165-71. Resumo
60. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec;130(6):1657-63. Resumo
61. Goodchild JH, Donaldson M. Methamphetamine abuse and dentistry: a review of the literature and presentation of a clinical case. Quintessence Int. 2007 Jul-Aug;38(7):583-90. Resumo
62. National Institute for Health and Care Excellence. Drug misuse in over 16s: brief interventions and self-help. Jul 2007 [internet publication].Texto completo
63. Public Health England. How to use the ASSIST-Lite screening tool to identify alcohol and drug use and tobacco smoking. Apr 2021 [internet publication].Texto completo
64. World Health Organization. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): manual for use in primary care. Jan 2010 [internet publication].Texto completo
65. Hargraves D, White C, Frederick R, et al. Implementing SBIRT (Screening, Brief Intervention and Referral to Treatment) in primary care: lessons learned from a multi-practice evaluation portfolio. Public Health Rev. 2017;38:31.Texto completo Resumo
66. American College of Surgeons. Best practices guidelines: screening and intervention for mental health disorders and substance use and misuse in the acute trauma patient. Dec 2022 [internet publication].Texto completo
67. US Preventive Services Task Force. Final recommendation statement. Unhealthy drug use: screening. Jun 2020 [internet publication].Texto completo
68. Levy SJ, Williams JF; Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016 Jul;138(1):e20161211.Texto completo Resumo
69. National Institute for Health and Care Excellence. Postnatal care. Apr 2021 [internet publication].Texto completo
70. McKay JR. Impact of continuing care on recovery from substance use disorder. Alcohol Res. 2021 Jan 21;41(1):01.Texto completo Resumo
71. Iturralde E, Weisner CM, Adams SR, et al. Patterns of health care use 5 years after an intervention linking patients in addiction treatment with a primary care practitioner. JAMA Netw Open. 2022 Nov 1;5(11):e2241338.Texto completo Resumo
72. Minozzi S, Saulle R, Amato L, et al. Psychosocial interventions for stimulant use disorder. Cochrane Database Syst Rev. 2024 Feb 15;2(2):CD011866.Texto completo Resumo
73. US Department of Veterans Affairs. VA/DoD clinical practice guidelines: management of substance use disorder (SUD). Aug 2021 [internet publication].Texto completo
74. United Nations Office on Drugs and Crime. UNODC treatment of stimulant use disorders: current practices and promising perspectives. May 2019 [internet publication].Texto completo
75. Shoptaw S, Reback CJ. Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy. J Urban Health. 2006 Nov;83(6):1151-7.Texto completo Resumo
76. Sherman SG, Sutcliffe C, Srirojn B, et al. Evaluation of a peer network intervention trial among young methamphetamine users in Chiang Mai, Thailand. Soc Sci Med. 2009 Jan;68(1):69-79.Texto completo Resumo
77. McGovern R, Newham JJ, Addison MT, et al. Effectiveness of psychosocial interventions for reducing parental substance misuse. Cochrane Database Syst Rev. 2021 Mar 16;3(3):CD012823.Texto completo Resumo
78. Stuart AM, Baker AL, Denham AMJ, et al. Psychological treatment for methamphetamine use and associated psychiatric symptom outcomes: a systematic review. J Subst Abuse Treat. 2020 Feb;109:61-79.Texto completo Resumo
79. De Crescenzo F, Ciabattini M, D'Alò GL, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis. PLoS Med. 2018 Dec;15(12):e1002715.Texto completo Resumo
80. Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006 Feb;101(2):267-74. Resumo
81. Brown HD, DeFulio A. Contingency management for the treatment of methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020 Nov 1;216:108307. Resumo
82. Ronsley C, Nolan S, Knight R, et al. Treatment of stimulant use disorder: a systematic review of reviews. PLoS One. 2020;15(6):e0234809.Texto completo Resumo
83. Rawson R, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002 Sep;23(2):145-50. Resumo
84. Roll JM, Petry NM, Stitzer ML, et al. Contingency for the treatment of methamphetamine use disorder. Am J Psychiatry. 2006 Nov;163(11):1993-9. Resumo
85. Bentzley BS, Han SS, Neuner S, et al. Comparison of treatments for cocaine use disorder among adults: a systematic review and meta-analysis. JAMA Netw Open. 2021 May 3;4(5):e218049.Texto completo Resumo
86. Higgins ST, Budney AJ, Bickel WK, et al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry. 1994 Jul;51(7):568-76. Resumo
87. Rawson RA, Huber A, McCann M, et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry. 2002 Sep;59(9):817-24.Texto completo Resumo
88. Prendergast M, Podus D, Finney J, et al. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006 Nov;101(11):1546-60. Resumo
89. Colfax G, Santos GM, Chu P, et al. Amphetamine-group substances and HIV. Lancet. 2010 Aug 7;376(9739):458-74. Resumo
90. McPherson SM, Burduli E, Smith CL, et al. A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies. Subst Abuse Rehabil. 2018;9:43-57.Texto completo Resumo
91. Kurti AN, Davis DR, Redner R, et al. A review of the literature on remote monitoring technology in incentive-based interventions for health-related behavior change. Transl Issues Psychol Sci. 2016 Jun;2(2):128-52.Texto completo Resumo
92. Harada T, Tsutomi H, Mori R, et al. Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders. Cochrane Database Syst Rev. 2018 Dec 22;(12):CD011315.Texto completo Resumo
93. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008 Feb;165(2):179-87.Texto completo Resumo
94. Maude-Griffin PM, Hohenstein JM, Humfleet GL, et al. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998 Oct;66(5):832-7. Resumo
95. Rohsenow DJ, Monti PM, Martin RA, et al. Brief coping skills treatment for cocaine abuse: 12-month substance use outcomes. J Consult Clin Psychol. 2000 Jun;68(3):515-20. Resumo
96. Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry. 1994 Mar;51(3):177-87. Resumo
97. Schwenker R, Dietrich CE, Hirpa S, et al. Motivational interviewing for substance use reduction. Cochrane Database Syst Rev. 2023 Dec 12;12(12):CD008063. Resumo
98. Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005 May 9;78(2):125-34. Resumo
99. AshaRani PV, Hombali A, Seow E, et al. Non-pharmacological interventions for methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020 Jul 1;212:108060.Texto completo Resumo
100. Amiri Z, Mirzaee B, Sabet M. Evaluating the efficacy of regulated 12-session Matrix Model in reducing susceptibility in methamphetamine-dependent individuals. Int J Med Res Health Sci. 2016;5(2):77-85.Texto completo
101. De Giorgi R, Cassar C, Loreto D'alò G, et al. Psychosocial interventions in stimulant use disorders: a systematic review and qualitative synthesis of randomized controlled trials. Riv Psichiatr. 2018 Sep-Oct;53(5):233-55.Texto completo Resumo
102. McLellan AT, Hagan TA, Meyers K, et al. "Intensive" outpatient substance abuse treatment: comparisons with "traditional" outpatient treatment. J Addict Dis. 1997;16(2):57-84. Resumo
103. Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry. 2009 May;22(3):263-8.Texto completo Resumo
104. Wouldes T, LaGasse L, Sheridan J, et al. Maternal methamphetamine use during pregnancy and child outcome: what do we know? N Z Med J. 2004 Nov 26;117(1206):U1180. Resumo
105. Eze N, Smith LM, LaGasse LL, et al. School-aged outcomes following prenatal methamphetamine exposure: 7.5-year follow-up from the Infant Development, Environment, and Lifestyle Study. J Pediatr. 2016 Mar;170:34-8.e1.Texto completo Resumo
106. World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Nov 2014 [internet publication].Texto completo
107. Washio Y, Atreyapurapu S, Hayashi Y, et al. Systematic review on use of health incentives in U.S. to change maternal health behavior. Prev Med. 2021 Apr;145:106442. Resumo
108. Siefried KJ, Acheson LS, Lintzeris N, et al. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. 2020 Apr;34(4):337-65.Texto completo Resumo
109. Soares E, Pereira FC. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups. Expert Opin Pharmacother. 2019 Dec;20(18):2273-93. Resumo
110. Lee NK, Jenner L, Harney A, et al. Pharmacotherapy for amphetamine dependence: a systematic review. Drug Alcohol Depend. 2018 Oct 1;191:309-37. Resumo
111. Chan B, Freeman M, Kondo K, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder - a systematic review and meta-analysis. Addiction. 2019 Dec;114(12):2122-36. Resumo
112. Shearer J, Darke S, Rodgers C, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009 Feb;104(2):224-33. Resumo
113. Longo M, Wickes W, Smout M, et al. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010 Jan;105(1):146-54. Resumo
114. Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014 Sep;109(9):1489-500.Texto completo Resumo
115. Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Jul;108(7):1279-86. Resumo
116. Solhi H, Jamilian HR, Kazemifar AM, et al. Methylphenidate vs. resperidone in treatment of methamphetamine dependence: a clinical trial. Saudi Pharm J. 2014 Jul;22(3):191-4.Texto completo Resumo
117. Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology. 2015 Sep;40(10):2347-56.Texto completo Resumo
118. Comer SD, Mogali S, Saccone PA, et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology. 2013 Nov;38(12):2427-38.Texto completo Resumo
119. Stoops WW, Rush CR. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Expert Rev Clin Pharmacol. 2014 May;7(3):363-74.Texto completo Resumo
120. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021 Jan 14;384(2):140-53.Texto completo Resumo
121. De La Garza R 2nd, Newton TF, Haile CN, et al. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):141-6. Resumo
122. Chang CH, Liou MF, Liu CY, et al. Efficacy of repetitive transcranial magnetic stimulation in patients with methamphetamine use disorder: a systematic review and meta-analysis of double-blind randomized controlled trials. Front Psychiatry. 2022 May 27;13:904252.Texto completo Resumo
123. Makani R, Pradhan B, Shah U, et al. Role of repetitive transcranial magnetic stimulation (rTMS) in treatment of addiction and related disorders: a systematic review. Curr Drug Abuse Rev. 2017;10(1):31-43. Resumo
124. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther. 2005 Oct;108(1):76-85. Resumo
125. Collins KC, Schlosburg JE, Bremer PT, et al. Methamphetamine vaccines: improvement through hapten design. J Med Chem. 2016 Apr 28;59(8):3878-85.Texto completo Resumo
126. Farahzadi MH, Moazen-Zadeh E, Razaghi E, et al. Riluzole for treatment of men with methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2019 Mar;33(3):305-15. Resumo
127. Goldberg SB, Pace B, Griskaitis M, et al. Mindfulness-based interventions for substance use disorders. Cochrane Database Syst Rev. 2021 Oct 20;1(10):CD011723.Texto completo Resumo
128. Maneesang W, Hengpraprom S, Kalayasiri R. Effectiveness of mindfulness-based therapy and counseling programs (MBTC) on relapses to methamphetamine dependence at a substance dependency treatment center. Psychiatry Res. 2022 Nov;317:114886. Resumo
129. Rostami R, Dehghani-Arani F. Neurofeedback training as a new method in treatment of crystal methamphetamine dependent patients: a preliminary study. Appl Psychophysiol Biofeedback. 2015 Sep;40(3):151-61. Resumo
130. Calabria BD, Degenhardt L, Briegleb C, et al. Systematic review of prospective studies investigating "remission" from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav. 2010 Aug;35(8):741-9. Resumo
131. Turnipseed SD, Richards JR, Kirk D, et al. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003 May;24(4):369-73. Resumo
132. Mortelmans LJM, Bogaerts PJM, Hellemans S, et al. Spontaneous pneumomediastinum and myocarditis following ecstasy use: a case report. Eur J Emerg Med. 2005 Feb;12(1):36-8. Resumo
133. Dickson SD, Thomas IC, Bhatia HS, et al. Methamphetamine-associated heart failure hospitalizations across the United States: geographic and social disparities. J Am Heart Assoc. 2021 Aug 17;10(16):e018370.Texto completo Resumo
134. Swalwell CI, Davis GG. Methamphetamine as a risk factor for acute aortic dissection. J Forensic Sci. 1999 Jan;44(1):23-6. Resumo
135. Rejali D, Glen P, Odom N. Pneumomediastinum following ecstasy (methylenedioxymethamphetamine, MDMA) ingestion in two people at the same "rave". J Laryngol Otol. 2002 Jan;116(1):75-6. Resumo
136. National Toxicology Program. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. NTP CERHR MON. 2005 Jul;(16):i-III-1.Texto completo Resumo
137. Tucker P. Substance misuse and early psychosis. Australas Psychiatry. 2009 Aug;17(4):291-4. Resumo
138. Silber BY, Croft RJ, Papafotiou K, et al. The effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology (Berl). 2006 Aug;187(2):154-69. Resumo
139. Sheridan J, Bennett S, Coggan C, et al. Injury with methamphetamine use: a review of the literature. Harm Reduct J. 2006 Mar 29;3:14.Texto completo Resumo
140. Fischer B, Haydon E, Rehm J, et al. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach - the case study of Canada. J Urban Health. 2004 Sep;81(3):428-47.Texto completo Resumo
141. Centers for Disease Control and Prevention. Adult immunization schedule by age: recommendations for ages 19 years or older, United States, 2024. Nov 2023 [internet publication].Texto completo
142. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update. 2021 [internet publication].Texto completo
O uso deste conteúdo está sujeito ao nosso aviso legal